Patient’s Journey: Experience with mCRPC and the Lutetium (Pluvicto) Shortage
E. David Crawford, MD, interviews Lon and his partner Kacy about Lon’s 5-year treatment experience with advanced prostate cancer.
Read MoreSelect Page
by E. David Crawford, MD | Apr 2023
E. David Crawford, MD, interviews Lon and his partner Kacy about Lon’s 5-year treatment experience with advanced prostate cancer.
Read Moreby Edwin M. Posadas | Mar 2023
E. David Crawford, MD, interviews Edwin M. Posadas, MD, FACP, on his clinical experience with lutetium.
Read Moreby Neal D. Shore, MD | Nov 2018
Neal D. Shore, MD, introduces a real-time high resolution micro-ultrasound system for calculating prostate malignancy risk levels and guiding prostate biopsies. He also compares accuracy and practical benefits of micro-ultrasound to conventional ultrasound and MRI-guided biopsy techniques.
Read Moreby Peter G. Schulam, MD, PhD | May 2018
Peter Schulam MD, PhD, compares and contrasts the Surveillance, Epidemiology, and End Results (SEER) database and the National Cancer Database (NCDB) in terms of reliability for assessing upper tract urothelial carcinoma (UTUC) outcomes and risk factors when determining whether to treat a patient with definitive therapy or the “Watchful Waiting” strategy.
Read Moreby Seth P. Lerner, MD | Apr 2018
Seth P. Lerner, MD, discusses standard of care treatments for UTUC, the quality of life burdens they pose, and the importance of elective nephron sparing to assuage those negative effects. He describes current and future nephron-sparing methods, especially the use of Mitomycin C (MitoGel), which is under review in the OLYMPUS trial.
Read Moreby Emmanuel S. Antonarakis, MD | Mar 2018
Dr. Emmanuel Antonarakis discusses treating chemo-naive metastatic hormone-sensitive prostate cancer and then discusses the impact of AR-V7 in CRPC.
Read Moreby Brian J. Moran, MD | Mar 2018
Brian Moran, MD, discusses focal brachytherapy, stereotactic transperineal prostate biopsy (STPB),...
Read Moreby Maha H. Hussain, MD, FACP, FASCO | Mar 2018
Dr. Maha H.A. Hussain, MBChB, reviews the PROSPER trial, which tested the efficacy and safety of enzalutamide in the setting of nonmetastatic CRPC. Following her summary, she and Dr. E. David Crawford, MD, engage in a question and answer session.
Read Moreby Patrick C. Walsh, MD | Feb 2018
In this presentation, Dr. Patrick Walsh expands upon Dr. Veda N. Giri’s introduction to the Philadelphia Prostate Cancer Consensus 2017. While she set forth the goals of the meeting and emphasized the importance of drafting centralized guidelines for genetic testing, Dr. Walsh focuses on PSA testing. He summarizes the past of PSA testing to give context to the urological community’s goals for the future.
Read Moreby Jack A. Schalken, PhD | Feb 2018
Jack A Schalken, PhD, and E. David Crawford, MD, discuss recent advances in non invasive liquid...
Read Moreby Scott T. Tagawa, MD | Feb 2018
Scott T. Tagawa, MD, Weill Cornell Medicine, provides an overview of radiogland therapy and...
Read Moreby E. David Crawford, MD | Dec 2017
NEXT GENERATIONnmCRPC Patient’s Journey: Experience with mCRPC and the Lutetium (Pluvicto)...
Read More